The range of issues related to the cooperation of the two enterprises was considered during the negotiations. Mundifarma Medical GmbH is a large international manufacturer of prolonged-release opioid analgesics (MST and DHC) used to treat severe pain in cancer patients. The FSUE Moscow Endocrine Plant is a domestic leader in the production of centrally-acting analgesics, which provides the major part of the demand in these drugs in healthcare facilities and the pharmacy network of the Russian Federation. Based on the results of the negotiations, the agreement was reached to develop mutually beneficial cooperation in the field of contract production, as well as to participate in joint projects on the development and implementation of innovative drugs.
Comment type is not specified in the component properties.